Products Affected - Description
Diltiazem Hydrochloride injection, Akorn
5 mg/mL, 5 mL vial, 10 count (NDC 17478-0937-05)
5 mg/mL, 10 mL vial, 10 count (NDC 17478-0937-10)
5 mg/mL, 25 mL vial, 1 count (NDC 17478-0937-25)
5 mg/mL, 25 mL vial, 10 count (NDC 17478-0937-26)
Diltiazem Hydrochloride injection, Hospira
5 mg/mL, 5 mL vial, 10 count (NDC 00409-1171-01)
5 mg/mL, 10 mL vial, 10 count (NDC 00409-1171-02)
Reason for the Shortage
- Akorn states the reason for the shortage is increased demand due to market conditions.
- Hospira states the reasons for the shortage are manufacturing delays and increases in demand.
- West-Ward had diltiazem injection on shortage due to manufacturing delays caused by increased demand due to current market conditions.
Diltiazem Hydrochloride lyophilized powder for solution for injection, Hospira
100 mg, ADD-Vantage vial, 10 count (NDC 00409-4350-03)
Diltiazem Hydrochloride injection, West-Ward
5 mg/mL, 5 mL vial, 10 count (NDC 00641-6013-10)
5 mg/mL, 10 mL vial, 10 count (NDC 00641-6014-10)
5 mg/mL, 25 mL vial, 10 count (NDC 00641-6015-10)
Estimated Resupply Dates
- Akorn has diltiazem 5 mg/mL 5 mL vials, 10 mL vials, and 25 mL vials in 1 count and 10 count available but with short-expiration dating of 3rd quarter 2017.
- Hospira has diltiazem 5 mg/mL 5 mL vials on back order and the company estimates a release date of 1st quarter 2017. The 5 mg/mL 10 mL vials are available in limited supply.
November 29, October 26, August 16, July 15, June 3, May 20, April 19 and 6, March 23, February 4, January 13, 2016; December 28, November 24, October 28, September 17 and 1, July 23, June 25, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins